Industry and News MMR Vaccines Market Research Report 2021 | Page 2

The MMR vaccine is generally administered to children around the age of one year, with a second
dose before starting school (i.e. age 4/5). The second dose is a dose to produce immunity in the
small number of persons (2-5%) who fail to develop measles immunity after the first dose.
Disease indication, included in the vaccines market are influenza, pneumococcal disease, diphtheria,
tetanus, and pertussis (DTP), rotavirus, hepatitis, polio, varicella, meningococcal disease, mumps,
measles, and rubella (MMR), human papilloma virus (HPV) infection, and others. The pneumococcal
disease segment is expected to account for the largest share of the vaccines market in 2016. High
incidence of pneumococcal infections is driving the growth of this market.
The key target audience for MMR vaccine market are vaccine manufacturers, vaccine research
institutes, clinical laboratories, vaccine associations, research and consulting firms, vaccine product
distributors, group purchasing organizations, vaccine raw material suppliers, immunization centers,
vaccine development institutes and organizations, hospitals and laboratories, biotechnology and
biopharmaceutical companies. On the basis of product, the MMR vaccines market is segmented into
monovalent vaccines and multivalent vaccines. The segment “monovalent vaccines” is expected to
account for the largest share of this market.
Get PDF with Technological Trends @
https://www.millioninsights.com/industry-reports/mmr-vaccine-market/request-sample
The large share of the market is attributed to rising prevalence of diseases and increasing
government and non-government initiatives for vaccine R&D activities. On the basis of application,
the MMR vaccines market is segmented into pediatrics, adolescents, adults, elderly and so on. On
the basis of geography, the MMR vaccines market is segmented into North America, Asia Pacific,
Europe, Latin America and Middle East & Africa.
Growth in the North America region is primarily driven by government initiatives for immunization
against diseases such as influenza and HPV in the North America countries. The key players of MMR
vaccines industry are AstellasPharma Inc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline,
Medlmmune LLC, Johnson & Johnson, Merck & CO, Pfizer, Sanofi Pasteur, Serum Institute and India
Pvt. Ltd.